While prostate tumors bearing genomic mutations of SPOP can only be treated using gene therapy at present, identification of AURKA as an upstream regulator of SPOP provides a powerful therapeutic opportunity for large number of PCa patients which harbor wild-type SPOP by targeting AURKA using small molecule inhibitors. The gene discussed is AURKA; the disease is prostate neoplasm.